Rtw Investments
Latest statistics and disclosures from Rtw Investments's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MDGL, INSM, PTGX, PTCT, ARGX, and represent 33.98% of Rtw Investments's stock portfolio.
- Added to shares of these 10 stocks: CGON (+$337M), CELC (+$284M), ERAS (+$259M), TNGX (+$247M), HNGE (+$61M), IRTC (+$57M), ISRG (+$55M), WAY (+$39M), CADL (+$32M), AKTS (+$29M).
- Started 9 new stock positions in IPSC, AKTS, AVTX, DNTH, DFTX, WAY, ATAI, CADL, OCGN.
- Reduced shares in these 10 stocks: PEN (-$269M), AXSM (-$162M), Apellis Pharmaceuticals (-$160M), , Masimo Corporation (-$89M), COGT (-$82M), RAPT (-$56M), NTRA (-$50M), SYK (-$48M), QURE (-$18M).
- Sold out of its positions in Allurion Technologies, AXSM, CRVS, PODD, IQV, Masimo Corporation, MNMD, PEN, RAPT, GPCR. TEM, Atai Life Sciences Nv.
- Rtw Investments was a net buyer of stock by $531M.
- Rtw Investments has $10B in assets under management (AUM), dropping by 0.67%.
- Central Index Key (CIK): 0001493215
Tip: Access up to 7 years of quarterly data
Positions held by Rtw Investments consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Rtw Investments
Rtw Investments holds 88 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals (MDGL) | 10.4 | $1.0B | 2.0M | 523.47 |
|
|
| Insmed Com Par $.01 (INSM) | 7.9 | $792M | 4.8M | 163.52 |
|
|
| Protagonist Therapeutics (PTGX) | 5.3 | $533M | 5.1M | 105.40 |
|
|
| Ptc Therapeutics I (PTCT) | 5.3 | $528M | 7.7M | 68.13 |
|
|
| Argenx Se Sponsored Adr (ARGX) | 5.2 | $518M | +5% | 709k | 730.25 |
|
| Cg Oncology (CGON) | 4.7 | $473M | +247% | 7.0M | 67.68 |
|
| Celcuity (CELC) | 3.5 | $347M | +452% | 3.0M | 114.14 |
|
| Tango Therapeutics (TNGX) | 2.8 | $278M | +791% | 13M | 20.92 |
|
| Erasca (ERAS) | 2.6 | $261M | +10917% | 16M | 16.18 |
|
| Natera (NTRA) | 2.5 | $250M | -16% | 1.3M | 199.99 |
|
| RadNet (RDNT) | 2.4 | $240M | +8% | 4.3M | 55.89 |
|
| Tarsus Pharmaceuticals (TARS) | 2.3 | $235M | 3.3M | 70.15 |
|
|
| Apogee Therapeutics (APGE) | 2.3 | $234M | +2% | 2.8M | 84.17 |
|
| Spyre Therapeutics Com New (SYRE) | 2.1 | $210M | 4.2M | 50.44 |
|
|
| Cogent Biosciences (COGT) | 2.1 | $210M | -28% | 5.5M | 38.49 |
|
| Irhythm Technologies (IRTC) | 2.0 | $197M | +41% | 1.7M | 118.02 |
|
| Stoke Therapeutics (STOK) | 1.8 | $183M | 5.6M | 32.56 |
|
|
| Cytokinetics Com New (CYTK) | 1.8 | $179M | 2.7M | 65.91 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 1.6 | $159M | 7.1M | 22.26 |
|
|
| Establishment Labs Holdings Ord (ESTA) | 1.5 | $151M | +2% | 2.7M | 56.78 |
|
| Apellis Pharmaceuticals | 1.5 | $148M | -51% | 3.7M | 40.23 |
|
| Immunocore Hldgs Ads (IMCR) | 1.5 | $147M | 4.9M | 30.15 |
|
|
| Repligen Corporation (RGEN) | 1.4 | $142M | +13% | 1.2M | 117.82 |
|
| Neurocrine Biosciences (NBIX) | 1.4 | $140M | 1.1M | 131.74 |
|
|
| Guardant Health (GH) | 1.4 | $137M | 1.5M | 92.37 |
|
|
| Immatics SHS (IMTX) | 1.3 | $127M | +12% | 13M | 9.84 |
|
| Zai Lab Adr (ZLAB) | 1.2 | $124M | -5% | 6.6M | 18.81 |
|
| Belite Bio Sponsored Ads (BLTE) | 1.1 | $114M | 715k | 159.44 |
|
|
| Intuitive Surgical Com New (ISRG) | 1.0 | $101M | +117% | 220k | 460.99 |
|
| Oruka Therapeutics (ORKA) | 1.0 | $101M | 2.1M | 49.05 |
|
|
| Gh Research Ordinary Shares (GHRS) | 0.8 | $83M | 5.9M | 14.06 |
|
|
| Xencor (XNCR) | 0.8 | $82M | 6.8M | 12.06 |
|
|
| Urogen Pharma (URGN) | 0.8 | $82M | 4.5M | 17.98 |
|
|
| Centessa Pharmaceuticals Sponsored Ads | 0.8 | $82M | +14% | 2.1M | 39.72 |
|
| Immunovant (IMVT) | 0.8 | $79M | 3.2M | 24.84 |
|
|
| Ultragenyx Pharmaceutical (RARE) | 0.8 | $76M | +21% | 3.6M | 20.95 |
|
| Hinge Health Cl A (HNGE) | 0.7 | $74M | +445% | 1.9M | 38.56 |
|
| Castle Biosciences (CSTL) | 0.7 | $68M | +30% | 2.8M | 24.55 |
|
| Rocket Pharmaceuticals (RCKT) | 0.6 | $63M | 18M | 3.58 |
|
|
| Taysha Gene Therapies Com Shs (TSHA) | 0.6 | $61M | -16% | 14M | 4.47 |
|
| Alkermes SHS (ALKS) | 0.6 | $59M | 1.7M | 35.36 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 0.6 | $59M | +21% | 11M | 5.53 |
|
| Kodiak Sciences (KOD) | 0.6 | $57M | 1.5M | 38.12 |
|
|
| Replimune Group (REPL) | 0.6 | $56M | +3% | 7.4M | 7.65 |
|
| Crinetics Pharmaceuticals In (CRNX) | 0.5 | $53M | +7% | 1.5M | 36.32 |
|
| Uniqure Nv SHS (QURE) | 0.4 | $42M | -30% | 2.6M | 16.35 |
|
| Waystar Holding Corp (WAY) | 0.4 | $39M | NEW | 1.6M | 24.11 |
|
| Arrowhead Pharmaceuticals (ARWR) | 0.4 | $37M | 586k | 62.70 |
|
|
| Health Sciences Acq Corp 2 (OBIO) | 0.4 | $35M | 8.3M | 4.25 |
|
|
| Verastem Com New (VSTM) | 0.3 | $35M | 6.6M | 5.30 |
|
|
| Evommune Com Shs (EVMN) | 0.3 | $35M | +17% | 1.5M | 22.99 |
|
| Stryker Corporation (SYK) | 0.3 | $33M | -59% | 100k | 328.59 |
|
| Savara (SVRA) | 0.3 | $33M | 6.0M | 5.46 |
|
|
| Candel Therapeutics (CADL) | 0.3 | $32M | NEW | 6.4M | 4.90 |
|
| Aquestive Therapeutics (AQST) | 0.3 | $31M | +18% | 7.4M | 4.15 |
|
| Aktis Oncology (AKTS) | 0.3 | $29M | NEW | 1.6M | 17.89 |
|
| Neurogene (NGNE) | 0.3 | $28M | 1.4M | 20.16 |
|
|
| Cullinan Oncology (CGEM) | 0.2 | $24M | 1.7M | 14.21 |
|
|
| Compass Therapeutics (CMPX) | 0.2 | $22M | +67% | 4.2M | 5.29 |
|
| Dianthus Therapeutics (DNTH) | 0.2 | $21M | NEW | 248k | 83.92 |
|
| Fulgent Genetics (FLGT) | 0.2 | $21M | +82% | 1.3M | 15.90 |
|
| Beta Bionics (BBNX) | 0.2 | $20M | -20% | 2.0M | 10.02 |
|
| Kymera Therapeutics (KYMR) | 0.2 | $20M | 240k | 83.29 |
|
|
| Century Therapeutics (IPSC) | 0.2 | $20M | NEW | 8.7M | 2.26 |
|
| Beam Therapeutics (BEAM) | 0.1 | $14M | 570k | 23.83 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.1 | $13M | NEW | 857k | 14.93 |
|
| Ocugen (OCGN) | 0.1 | $12M | NEW | 6.7M | 1.81 |
|
| Heartflow Inc/Sh (HTFL) | 0.1 | $12M | 495k | 24.33 |
|
|
| Wave Life Sciences SHS (WVE) | 0.1 | $9.8M | 1.4M | 7.25 |
|
|
| Perceptive Cap Solutions Cor Cl A Ord Shs (PCSC) | 0.1 | $8.1M | 743k | 10.97 |
|
|
| Jade Biosciences Com New (JBIO) | 0.1 | $8.1M | -60% | 573k | 14.05 |
|
| Capricor Therapeutics Com New (CAPR) | 0.1 | $7.6M | 250k | 30.40 |
|
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $7.5M | +152% | 6.3M | 1.19 |
|
| Kalaris Therapeutics (KLRS) | 0.1 | $7.5M | 1.3M | 5.77 |
|
|
| Inventiva Sa Ads (IVA) | 0.1 | $7.2M | 1.3M | 5.55 |
|
|
| Ataibeckley Com Shs (ATAI) | 0.1 | $7.1M | NEW | 2.0M | 3.54 |
|
| Crescent Biopharma (CBIO) | 0.1 | $6.8M | 373k | 18.37 |
|
|
| Larimar Therapeutics (LRMR) | 0.1 | $6.8M | -52% | 1.5M | 4.50 |
|
| Tenax Therapeutics Com New (TENX) | 0.1 | $5.9M | -2% | 370k | 15.99 |
|
| Definium Therapeutics Com Shs (DFTX) | 0.1 | $5.7M | NEW | 300k | 18.90 |
|
| Lumexa Imaging Holdings (LMRI) | 0.1 | $5.6M | 650k | 8.60 |
|
|
| 4d Molecular Therapeutics In (FDMT) | 0.0 | $4.4M | 476k | 9.31 |
|
|
| Medline Com Cl A (MDLN) | 0.0 | $3.1M | 70k | 44.50 |
|
|
| Omada Health (OMDA) | 0.0 | $2.5M | 200k | 12.57 |
|
|
| Disc Medicine (IRON) | 0.0 | $1.9M | 30k | 63.94 |
|
|
| Imagenebio (IMA) | 0.0 | $1.7M | 334k | 5.00 |
|
|
| Exagen (XGN) | 0.0 | $1.2M | -50% | 395k | 3.00 |
|
| Rocket Pharmaceuticals *w Exp 09/02/202 (RCKTW) | 0.0 | $7.2k | 350k | 0.02 |
|
Past Filings by Rtw Investments
SEC 13F filings are viewable for Rtw Investments going back to 2014
- Rtw Investments 2026 Q1 filed May 15, 2026
- Rtw Investments 2025 Q4 filed Feb. 17, 2026
- Rtw Investments 2025 Q3 filed Nov. 14, 2025
- Rtw Investments 2025 Q2 filed Aug. 14, 2025
- Rtw Investments 2025 Q1 filed May 15, 2025
- Rtw Investments 2024 Q4 filed Feb. 14, 2025
- Rtw Investments 2024 Q3 filed Nov. 14, 2024
- Rtw Investments 2024 Q2 filed Aug. 14, 2024
- Rtw Investments 2024 Q1 filed May 15, 2024
- Rtw Investments 2023 Q4 filed Feb. 14, 2024
- Rtw Investments 2023 Q3 filed Nov. 14, 2023
- Rtw Investments 2023 Q2 filed Aug. 14, 2023
- Rtw Investments 2023 Q1 filed May 15, 2023
- Rtw Investments 2022 Q4 filed Feb. 14, 2023
- Rtw Investments 2022 Q3 filed Nov. 14, 2022
- Rtw Investments 2022 Q2 filed Aug. 15, 2022